Search results for Lorvotuzumab ELISA Kit
Lorvotuzumab ELISA Kit, ProteoGenix, KPTX181
Description of Lorvotuzumab ELISA Kit The Structure of Lorvotuzumab ELISA Kit Lorvotuzumab ELISA Kit is a highly specific and sensitive assay designed for the detection and quantification of lorvotuzumab in various biological samples. Lorvotuzumab is a monoclonal antibody that targets the cell surface protein CD56, which is overexpressed in many types of cancer cells. The ELISA kit is based on the principle of enzyme-linked immunosorbent assay (ELISA), where lorvotuzumab is captured by a specific antibody and then detected using a secondary antibody conjugated to an enzyme. The kit contains all the necessary components for the ELISA assay, including lorvotuzumab-coated microplates, standards, controls, and reagents for sample preparation and detection. The lorvotuzumab-coated microplates are designed to specifically bind to lorvotuzumab in the sample, while the standards and controls are used to generate a standard curve and validate the assay performance. The Activity of Lorvotuzumab ELISA Kit The lorvotuzumab ELISA kit is a highly sensitive and specific assay that allows for the accurate detection and quantification of lorvotuzumab in various biological samples. The assay is based on the principle of sandwich ELISA, where lorvotuzumab is captured by a specific antibody coated on the microplate and then detected using a secondary antibody conjugated to an enzyme. The enzyme catalyzes a colorimetric reaction, which can be measured using a spectrophotometer, and the intensity of the color is directly proportional to the amount of lorvotuzumab present in the sample. The ELISA kit has a wide dynamic range and can detect lorvotuzumab in a range of 0.1-10 ng/mL. The sensitivity of the assay is 0.05 ng/mL, making it highly sensitive for detecting even low levels of lorvotuzumab. The assay also has a high specificity, as it only detects lorvotuzumab and not other proteins or antibodies present in the sample. The Application of Lorvotuzumab ELISA Kit Lorvotuzumab ELISA Kit has a wide range of applications in the field of cancer research and drug development. It can be used to measure the levels of lorvotuzumab in various biological samples, such as serum, plasma, and cell culture supernatants. This allows for the monitoring of lorvotuzumab levels in patients receiving lorvotuzumab therapy or in preclinical studies evaluating the efficacy of lorvotuzumab in cancer treatment. The ELISA kit can also be used to measure the pharmacokinetics (PK) and pharmacodynamics (PD) of lorvotuzumab. PK studies involve measuring the concentration of lorvotuzumab over time, which can provide valuable information on its absorption, distribution, metabolism, and elimination in the body. PD studies, on the other hand, measure the effect of lorvotuzumab on its target, CD56, and can provide insights into its mechanism of action. Furthermore, the lorvotuzumab ELISA kit can be used in the development and optimization of lorvotuzumab-based therapies. It can be used to measure the levels of lorvotuzumab in different formulations and determine the stability of the antibody under different storage conditions. This information is crucial for ensuring the quality and efficacy of lorvotuzumab-based drugs. In conclusion, Lorvotuzumab ELISA Kit is a valuable tool for the detection and quantification of lorvotuzumab in various biological samples. Its high sensitivity and specificity make it an ideal choice for monitoring lorvotuzumab levels in patients and in preclinical studies, as well as for PK/PD studies and drug development.
Host
Reactivity
Applications
Conjugation
Lorvotuzumab ELISA Kit, Abbexa, abx395070
Lorvotuzumab ELISA Kit is a quantitative ELISA kit for detection of Lorvotuzumab.Lorvotuzumab mertansine (IMGN901, BB10901, huN901-DM1) is an antibody-drug conjugate (ADC) composed of the cytotoxic maytansinoid derivative, DM1, conjugated to the humanized N901 monoclonal antibody (lorvotuzumab, huN901), which binds CD56 with high affinity. DM1 conjugated to lorvotuzumab via a stable disulfide SPP linker (When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine). It was developed by ImmunoGen, Inc. Lorvotuzumab mertansine is designed for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer). It has been granted orphan drug status for Merkel cell carcinoma and has reported encouraging Phase II results for small-cell lung cancer (SCLC). Once bound to CD56 on the surface of the target cell, the conjugate is internalized, the linker is cleaved, DM1 is released which in turn inhibits tubulin polymerization and results in cell death. Maytansine is a natural product, originally derived from the Ethiopian shrub Maytenus serrata. Maytansine inhibits tubulin polymerization, and is approximately 200-1,000 fold more cytotoxic than the Vinca alkaloids. Maytansine is clinically active but its narrow therapeutic window precluded further clinical development. Conjugation to an antibody and intracellular delivery could take advantage of the cytotoxic potency and expand the therapeutic window leading to greater tumor cell death with less overall toxicity. The maytansine derivative DM1 was developed specifically for use in ADCs.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.